AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis ...
December 04 2017 - 7:00AM
Business Wire
Conference Theme is “The Path Forward for
Regenerative Medicine: Traversing the Lab to the Patient”
AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc.
(NYSE American: BTX) announced today that Chief Executive Officer
Michael D. West, Ph.D., is participating on a roundtable panel at
Termis Americas’ annual conference & exhibition on Tissue
Engineering & Regenerative Medicine, December 6 in Charlotte,
North Carolina. Dr. West will describe the AgeX product pipeline,
in particular, the emerging field of induced tissue regeneration
(iTR). Dr. West’s presentation will be available for viewing at
www.agexinc.com.
This year’s conference will focus on the theme, “The Path
Forward for Regenerative Medicine: Traversing the Lab to the
Patient.” Dr. West will participate in a panel discussion titled
“The Coming-of-Age Story of Cell Therapy: Is the Field Mature
Enough for Prime Time?” 10:00-11:00 AM EST.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE
American: BTX), is a biotechnology company applying technology
relating to cellular immortality and regenerative biology to aging
and age-related diseases. The company has three initial areas of
product development: pluripotent stem cell-derived brown adipocytes
(AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue
Regeneration (iTR). Initial planned indications for these products
are Type 2 diabetes, cardiac ischemia, and cancer respectively. For
more information, please visit www.agexinc.com or connect with the
company on Twitter or Facebook.
About BioTime
BioTime is a late stage clinical biotechnology company
focused on developing and commercializing products addressing
degenerative diseases. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and cell
and drug delivery. Its clinical programs are based on two platform
technologies: pluripotent cells, which can become any type of cell
in the human body, and cell/drug delivery. Renevia®, a cell
delivery product, met its primary endpoint in an EU pivotal
clinical trial for the treatment of facial lipoatrophy in HIV
patients earlier this year. Submission for approval of
Renevia® in the EU is expected to be early 2018, with possible
approval and commercial launch in 2018. There were no device
related serious adverse events reported. OpRegen®, a retinal
pigment epithelium transplant therapy, is in a Phase I/IIa
multicenter trial for the treatment of dry age-related macular
degeneration, the leading cause of blindness in developing
countries. There were no related serious adverse events
reported. BioTime also has significant equity holdings in
two publicly traded companies, Asterias Biotherapeutics,
Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE
American: OCX), and a private company, AgeX Therapeutics,
Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications,
please click on the following link to join the Company’s email
alert list: http://news.biotime.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171204005317/en/
Investor Contact for BioTime:David Nakasone,
510-871-4188Dnakasone@biotimeinc.comorMedia Contact for AgeX:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024